Last updated 37 hours ago

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

1280 patients around the world
Available in Puerto Rico, Guatemala, United States, Mexico
AbbVie
2Research sites
1280Patients around the world

This study is for people with

Hidradenitis suppurativa

Requirements for the patient

From 12 Years
All Gender

Medical requirements

Diagnosis of moderate to severe HS for at least 6 months prior to Baseline as determined by the investigator.
Total abscess and inflammatory nodule count of ≥ 5 at Baseline.
Hidradenitis suppurativa lesions present in at least two distinct anatomic areas at Baseline.
At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.
Any evidence of Hepatitis B virus or hepatitis C virus infection.
Confirmed positive anti-HIV antibody test.
Evidence of active tuberculosis or meets tuberculosis exclusionary parameter.

Sites

Dermos
Recruiting
Zone 15, Guatemala City, Guatemala
Eukarya PharmaSite
Recruiting
De La Clínica 2520, Sertoma, 64718 Monterrey, N.L.
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy